Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Colon Cancer
Clinic's participation in colon cancer drug study provides access to new therapy
September 5th, 2004
Ocala Oncology Center, an affiliate of U.S. Oncology, Inc., (Nasdaq:USON), is bringing patients in the community a cutting-edge colon cancer therapy that in clinical trials has shown to be effective in improving colon cancer survival rates. Thomas H. Cartwright, MD, a medical oncologist at Ocala Oncology Center in Ocala, Florida, was a principal investigator for the study, lead by Genentech, using a new drug Avastin that inhibits tumor growth. U.S. Oncology enrolled more than 100 patients out of the 800 patients in the study. Cartwright played a key role in the study. He was responsible for U.S. Oncology patient enrollment, monitoring safety issues,...
Source: Medical Letter on the CDC & FDA (2004-09-05)
|
